Treatment of obesity using non-daily administration of 6-O-(4-dimethylaminoethoxy) cinnamoyl fumagillol
US-9173865-B2 · Nov 3, 2015 · US
Methods of treating an overweight or obese subject
US9925166B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9925166-B2 |
| Application number | US-201615093953-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 8, 2016 |
| Priority date | Jul 18, 2008 |
| Publication date | Mar 27, 2018 |
| Grant date | Mar 27, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention herein generally relates to pharmaceutical formulations and methods of treating an overweight or obese subject, and overweight- or obesity-related conditions.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating an overweight or obese subject in need thereof, the method comprising: orally administering to the subject a pharmaceutical composition comprising about 0.001 mg/kg to about 1 mg/kg of body weight per day of a compound selected from the group consisting of fumagillin, fumagillol, and salts thereof, and a pharmaceutically acceptable excipient. 2. The method according to claim 1 , wherein the subject is a human. 3. A method of treating an overweight or obese subject in need thereof comprising orally treating the subject with about 0.001 mg/kg to about 1 mg/kg of body weight per day of a compound selected from the group consisting of fumagillin, fumagillol and salts thereof.
Assignees
Inventors
Classifications
Anorexiants; Antiobesity agents · CPC title
Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
- A61K31/336Primary
having three-membered rings, e.g. oxirane, fumagillin · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9925166B2 cover?
- The invention herein generally relates to pharmaceutical formulations and methods of treating an overweight or obese subject, and overweight- or obesity-related conditions.
- Who is the assignee on this patent?
- Zafgen Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/336. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).